BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33182023)

  • 1. Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis.
    Lin X; Lin K; Lin C; Wang J; Tang Y
    Int Immunopharmacol; 2020 Nov; 88():106946. PubMed ID: 33182023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
    Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
    Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.
    Yang H; Zhou X; Sun L; Mao Y
    Front Oncol; 2019; 9():47. PubMed ID: 30891423
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic Value of S100P Expression in Patients With Digestive System Cancers: A Meta-Analysis.
    Liu BX; Tang CT; Dai XJ; Zeng L; Cheng F; Chen Y; Zeng C
    Front Oncol; 2021; 11():593728. PubMed ID: 33747914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
    Yang L; Xue R; Pan C
    Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
    Dai C; Wang M; Lu J; Dai Z; Lin S; Yang P; Tian T; Liu X; Min W; Dai Z
    Onco Targets Ther; 2017; 10():3625-3634. PubMed ID: 28769571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of decreased NDRG1 expression in patients with digestive system cancers: A meta-analysis.
    Chen K; Liu XH; Wang FR; Liu HP; Huang ZP; Chen X
    Medicine (Baltimore); 2018 Oct; 97(41):e12455. PubMed ID: 30313035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
    Zhang F; Gong W
    Int Immunopharmacol; 2020 Jun; 83():106481. PubMed ID: 32339986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
    Wang Q; Liu F; Liu L
    Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
    Liu X; Shan C; Song Y; Du J
    Front Oncol; 2019; 9():1111. PubMed ID: 31709181
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
    Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
    Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
    Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
    Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
    Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M
    Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of microRNA-135 in patients with digestive system cancers: a systematic review and meta-analysis.
    Chao C; Sang C; Wang M; Wang Z; Li Y; Luo G; Zhang X
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31803920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of NEK2 overexpression in digestive system cancers: a meta-analysis and systematic review.
    Ren Q; Li B; Liu M; Hu Z; Wang Y
    Onco Targets Ther; 2018; 11():7169-7178. PubMed ID: 30425509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.